Study of a new treatment for advanced cancers with c-MET protein
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests a new radioactive treatment for people with advanced solid tumors, such as certain lung, colon, head and neck, or bile duct cancers, that have stopped responding to standard treatments. The treatment targets a protein called c-MET found on cancer cells, aiming to deliver radiation directly to the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have an advanced or metastatic cancer that has not been cured by surgery, radiation, or other treatments.
- Your cancer type must be one of the following: non-squamous non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, or bile duct cancer.
- Your cancer must have grown after at least one previous treatment, and you cannot receive standard treatments anymore.
- Your tumor must test positive for c-MET protein, meaning a lab test shows a moderate to high level on at least half of the cancer cells.
- You must be generally well enough to do daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent called FL-261 to help doctors see and stage cancers more clearly. If you have a known or suspected cancer like lung, colon, or head and neck cancer, this study may improve how your cancer is evaluated.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This study tests a new imaging agent (a special dye) that might help doctors see tumors more clearly in people with certain advanced cancers. You would receive the dye and then have scans to see if it highlights cancer areas.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This study tests a new drug called MGC028 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.